Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence?A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)?